Petrylak Daniel P
Columbia University Medical Center, College of Physicians and Surgeons, New York, New York 10032-3788, USA.
Urology. 2005 May;65(5 Suppl):3-7; discussion 7-8. doi: 10.1016/j.urology.2005.03.053.
Since the publication of the Southwest Oncology Group (SWOG) 99-16 and TAX 327 studies, which demonstrated a survival benefit for docetaxel-based therapy, clinicians for the first time have a therapy to offer men with metastatic prostate cancer that is not merely palliative in its effects. Phase 2 and phase 3 trials are now building on the findings of SWOG 99-16 and TAX 327 by evaluating the potential of combination taxane-based therapies, such as docetaxel plus high-dose calcitriol, docetaxel-estramustine-bevacizumab, and docetaxel-thalidomide. The optimal timing of docetaxel-based chemotherapy is still unknown, as there are no prospective clinical trial data to indicate whether earlier treatment (eg, at the time of prostate-specific antigen failure) is more or less effective than later treatment (eg, in metastatic and/or symptomatic disease).
自西南肿瘤协作组（SWOG）99 - 16研究和TAX 327研究发表以来，这两项研究证明了基于多西他赛的治疗具有生存获益，临床医生首次拥有了一种对转移性前列腺癌男性患者有效的治疗方法，其效果不仅仅是姑息性的。目前，2期和3期试验正在基于SWOG 99 - 16和TAX 327的研究结果，评估基于紫杉烷联合疗法的潜力，如多西他赛加小剂量骨化三醇、多西他赛 - 雌莫司汀 - 贝伐单抗以及多西他赛 - 沙利度胺。基于多西他赛的化疗的最佳时机仍然未知，因为尚无前瞻性临床试验数据表明早期治疗（例如在前列腺特异性抗原失败时）与晚期治疗（例如在转移性和/或有症状疾病时）相比，疗效是更好还是更差。
